PUBLICATIONS
Original Article and Case Reports
1) Takahashi Y, Fuda H, Yanai H, Akita H, Shuping H, Chiba H, Matsuno K: Significance of
membrane glycoproteins in platelet interaction with oxidized low-density lipoprotein. Semin Thromb Hemost 24:251-253, 1998
2) Yanai H, Chiba H, Morimoto M, Jamieson GA, Matsuno K: Type I CD36 deficiency in humans is not associated with insulin resistance syndrome. Thromb Haemost 83:786, 2000
3) Yasuda S, Tsutsumi A, Chiba H, Yanai H, Miyoshi Y, Takeuchi R, Horita T, Atsumi T, Ichikawa K, Matsuura E, Koike T: beta(2)-glycoprotein I deficiency:prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis 152:337-346, 2000
4) Yanai H, Chiba H, Morimoto M, Abe K, Fujiwara H, Fuda H, Hui SP, Takahashi Y, Akita H, Jamieson GA, Kobayashi K, Matsuno K: Human CD36 deficiency is associated with elevation in low-density lipoprotein-cholesterol. Am J Med Genet 93:299-304, 2000.
5) Yanai H, Chiba H, Fujiwara H, Morimoto M, Abe K, Yoshida S, Takahashi Y, Fuda H, Hui SP, Akita H, Kobayashi K, Matsuno K: Phenotype-genotype correlation in CD36 deficiency types I and II. Thromb Haemost 84:436-441, 2000
6) Yanai H, Chiba H, Fujiwara H, Morimoto M, Takahashi Y, Hui SP, Fuda H, Akita H, Kurosawa T, Kobayashi K, Matsuno K: Metabolic changes in human CD36 deficiency displayed by glucose loading. Thromb Haemost 86:995-999, 2001
7) Shinohara T, Yanai H, Hidaka T, Suzuki K, Ohsuzu F: Acute congestive heart failure associated with a limited form of systemic sclerosis and primary biliary cirrhosis. Intern Med 40:73-76, 2001
8) Chiba H, Yanai H, Fujiwara H, Matsuno K, Kobayashi K: CD36 deficiency and insulin resistance. Lancet 358:243-244, 2001
9) Nagasaka H, Chiba H, Kikuta H, Akita H, Takahashi Y, Yanai H, Hui SP, Fuda H, Fujiwara H, Kobayashi K: Unique character and metabolism of high density lipoprotein (HDL) in fetus. Atherosclerosis 161:215-223, 2002
10) Shimizu C*, Fuda H*, Yanai H*, Strott CA (*equally contribution): Conservation of the hydroxysteroid sulfotransferase SULT2B1 gene structure in the mouse: pre-and postnatal expression, kinetic analysis of isoforms, and comparison with prototypical SULT2A1. Endocrinology 144:1186-1193, 2003.
11) Yanai H, Morimoto M: Significant association between fluctuations in serum urate and high
density lipoprotein cholesterol during exhaustive training. Br J Sports Med 37:370, 2003
12) Morimoto M, Yanai H, Shukuya K, Chiba H, Kobayashi K, Matsuno K: Effects of midstream
collection and the menstrual cycle on urine particles and dipstick urinalysis among healthy females. Clin Chem 49:188-190, 2003
13) Morimoto M, Yanai H, Chiba H, Matsuno K, Shukuya K: Importance of midstream clean-catch
technique for urinalysis, reconfirmed by urinary flow cytometry. Clin Chim Acta 333:101-102, 2003
14) Yanai H, Morimoto M: Diagnosis of nonalcoholic fatty liver disease. JAMA 290:1577, 2003.
15) Yanai H, Morimoto M: The effect of ascorbate on serum lipids?and urate metabolism during
exhaustive training. Clin Sci(Lond) 106:107-109, 2004
16) Yanai H, Javitt NB, Higashi Y, Fuda H, Strott CA: Expression of cholesterol sulfotransferease in human platelets. Circulation 109:92-96, 2004.
17) Higashi Y, Fuda H, Yanai H, Lee Y, Fukushige T, Kanzaki T, Strott CA: Expression of cholesterol sulfotransferase (SULT2B1b) in human skin and primary cultures of human epidermal keratinocytes. J Invest Derm 122:1207-1213, 2004.
18) Fujiwara H, Yanai H, Morimoto M: Significant influence of smoking on the mood of volunteers
who had the common cold. J Affect Dis 81:293-294, 2004
19) Nagasaka H, Yorifuji T, Egawa H, Yanai H, Fujisawa T, Kosugiyama K, Matsui A, Hasegawa
M, Okada T, Takayanagi M, Chiba H, Kobayashi K: Evaluation of risk of atherosclerosis in
Alagille syndrome and progressive familial intrahepatic cholestasis: two congenital cholestatic diseases with different lipoprotein metabolisms. J Pediatr 146:329- 335, 2005
20) Morimoto M, Yanai H, Matsuno K: Morphologic changes in urine particles during the menstrual
cycle. Clin Chem 51:1081-1082, 2005
21) Yanai H, Yoshida H, Fujiwara H, Yoshida S, Fuda H, Hui SP, Tada N, Chiba H: Oxidized
low-density lipoprotein upregulates GM2 activator protein gene expression. Am J Biochem
Biotech 1:90-94, 2005
22) Yanai H, Ohashi K, Otani K, Koyama T: Colonic diverticular haemorrhage is associated with
atherosclerosis. QJM 98:915-916, 2005
23) Yoshida H, Yanai H, Shoda T, Furutani N, Sato N, Tada N: Effects of Simvastatin 20 mg/d
on serum lipid profiles in Japanese hyperlipidemic patients: A prospective, open-Label pilot study. Curr Ther Res Clin Exp 66:613-629, 2005
24) Hirowatari Y, Yoshida H, Ogura Y, Yanai H, Kurosawa H, Tada N: Characteristics of
lipoprotein peak x eluted from a column with the eluent of high-magnesium ion concentration
in lipoprotein analysis using the cation-exchange chromatography. Am J Biochem & Biotech
1:154-160, 2005
25) Yanai H, Yoshida H, Tada N: Body-mass index and gastroesophageal reflux in women. N Engl
J Med 355:848-849, 2006
26) Yanai H, Yoshida H, Ohashi K, Otani K, Sekine T, Tada N, Koyama T: A teenager with
abdominal pain and soft-tissue emphysema. CMAJ 174:624, 2006
27) Kurosawa H, Yoshida H, Yanai H, Ogura Y, Hirowatari Y, Tada N: Comparative study between
anion-exchange HPLC and homogeneous assay methods in regard to the accuracy of high- and
low-density lipoprotein cholesterol measurement. Clin Biochem 40:1291-1296, 2007.
28) Yanai H, Yoshida H, Tomono Y, Tada N: Diacylglycerol oil for apolipoprotein C-II deficiency.
QJM 100:247-248, 2007.
29) Yanai H, Yoshida H, Hirowatari Y, Tomono Y, Tada N: Oxidized low density lipoprotein
elevates platelet serotonin release. Am J Hematol 82:686-687, 2007
30) Yanai H, Watanabe I, Ishii K, Morimoto M, Fujiwara H, Yoshida S, Hui SP, Matsuno K, Chiba
H: Attenuated aerobic exercise capacity in CD36 deficiency. J Med Genet 44:445-447, 2007
31) Yanai H, Yoshida H, Tomono Y, Hirowatari Y, Kurosawa H, Matsumoto A, Tada N: Effects of
diacylglycerol on glucose, lipid metabolism, and plasma serotonin levels in lean Japanese.
Obesity (Silver Spring) 16:47-51, 2008
32) Yanai H, Yoshida H, Tomono Y, Tada N: Severe hypoglycemia in a patient with anorexia
nervosa. Eat Weight Disord 3:e1-3, 2008
33) Yoshida H, Kurosawa H, Hirowatari Y, Ogura Y, Ikewaki K, Abe I, Saikawa S, Domitsu K, Ito
K, Yanai H, Tada N: Characteristic comparison of triglyceride-rich remnant lipoprotein
measurement between a new homogeneous assay (RemL-C) and a conventional
immunoseparation method (RLP-C). Lipids Health Dis 7:18, 2008
34) Yanai H, Tada N: A simple hepatic cyst with elevated serum and cyst fluid CA19-9 levels:
a case report. J Med Case Reports 2:329, 2008
35) Yanai H, Chiba H, Matsuno K: Elevated plasma plasminogen activator inhibitor-1 in CD36
deficiency. Diabetes Care 31:e72, 2008.
36) Yanai H, Furutani N, Ito K, Yoshida H, Tada N: Scintigraphic findings and serum matrix
metalloproteinase 3 and vascular endothelial growth factor levels in patients with
polymyalgia rheumatica. The Open General and Internal Medicine 3:53-57, 2009
37) Yanai H, Furutani N, Tada N: Mediastinal abscess and supprative thrombophlebitis possibly
because of an accidental inhalation of paraquat. BMJ Case Reports 2009
(doi:10.1136/bcr.08.2008.0836).
38) Yanai H, Furutani N, Yoshida H, Tada N: Myositis, vasculitis, hepatic dysfunction in
adult-onset Still’s disease. Case Reports in Medicine 10:1155, 2009
39) Yanai H, Furutani N, Yoshida H, Tada N: Aseptic spondylodiscitis in a patient with
polymyalgia rheumatica. BMJ Case Reports 2009 (doi.10.1136/bcr.02.2009.1555).
40) Yanai H, Yoshida H, Tada N: Clinical, radiological, and biochemical characteristics in
patients with diseases mimicking polymyalgia rheumatica. Clin Interv Aging 4:391-395,
2009
41) Yanai H, Tomono Y, Ito K, Hirowatari Y, Yoshida H, Tada N: A molecular mechanism for
diacylglycerol-mediated promotion of negative caloric balance. Diabetes, Metabolic
Syndrome and Obesity: Targets and Therapy 3:1-6, 2010
42) Yoshida H, Yanai H, Ito K, Tomono Y, Koikeda T, Tsukahara H, Tada N: Administration of
natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild
hyperlipidemia. Atherosclerosis 209:520-523, 2010
43) Hirowatari Y, Yoshida H, Kurosawa H, Shimura Y, Yanai H, Tada N: Analysis of cholesterol
levels in lipoprotein(a) with anion-exchange chromatography. J Lipid Res 51:1237-1243,
2010
44) Yanai H, Kaneko H, Yoshida H, Tada N: A significant association between an impaired
glucose metabolism and polymyalgia rheumatica. J Atheroscler Thromb 17:1108-1109, 2010
45) Otani K, Kasuga Y, Kimura Y, Mukaide M, Yanai H, Koyama T, Fujise K; Hepatitis B surface
antigen is a better monitor of infectivity compared with antibody to hepatitis B core
antigen in hemodialysis patients. Ther Apher Dial 14:434-435, 2010
46) Yanai H, Masui Y, Yoshikawa R, Kunimatsu J, Kaneko H: Dipeptidyl peptidase-4 inhibitor
for steroid-induced diabetes. World J Diabetes 1:99-100, 2010
47) Yanai H: Sitagliptin in treatment of diabetes complicated by chronic hepatitis C.
Hepatobiliary Pancreat Dis Int 9:346-347, 2010
48) Yoshida H, Ishikawa T, Suto M, Kurosawa H, Hirowatari Y, Ito K, Yanai H, Tada N, Suzuki
M: Effects of Supervised Aerobic Exercise Training on Serum Adiponectin and Parameters
of Lipid and Glucose Metabolism in Subjects with Moderate Dyslipidemia. J Atheroscler
Thromb 17:1160-1166, 2010
49) Yanai H, Okamoto S, Kunimatsu J: Autoimmune polyglandular syndrome type 3 complicated by
mineralocorticoid-responsive hyponatremia of the elderly. World J Diabetes 1:135-136,
2010
50) Yanai H: Diabetic ketoacidosis in a patient underwent distal pancreatectomy. Hepatobiliary
Pancreat Dis Int 9:570, 2010
51) Yanai H and Yamazaki H: Grave’s Ophthalmopathy in the Absence of Abnormal Thyroid Hormone
and Thyrotropin Levels and Thyrotropin Receptor Antibody. Thyroid Science 5:1-3, 2010
52) Yanai H, Yoshikawa R: Silent aspiration pneumonitis due to Kussmaul breathing in diabetic
ketoacidosis. Case Study Case Rep 1:154-156, 2011
53) Adachi H, Yanai H (corresponding author), Ichinose T, Tanaka Y, Takakura H, Honda K: The
Development of Infective Endocarditis and Oral Dyskinesia in a Type 2 Diabetic Patient.
J Med Cases 2:240-242, 2011
54) Nagasaka H, Yorifuji T, Takatani T, Tsukahara H, Yanai H, Hirano K, Hui SP, Hirayama S,
Ito T, Chiba H, and Miida T: CD36 deficiency predisposing young children to fasting
hypoglycemia. Metabolism 60:881-887, 2011
55) Yanai H and Sekine K: Emphysematous Pyelonephritis in a Patient with Hyperosmolar
Hyperglycemic Syndrome. J Med Cases 2:37-38, 2011
56) Yanai H, Yoshimi T, Honda R: Effective Switch From Twice-Daily Pre-Mixed Insulin 50/50
to Liraglutide to Achieve a Good Glycemic Control in Type 2 Diabetes. J Med Cases 2:76-
80, 2011
57) Yanai H, Moriyama S: Elevated pancreatic enzymes, IgM, soluble interleukin-2 receptor in
anti-GADab(+) type 1 diabetes. World J Diabetes 2:75-76, 2011
58) Yanai H, Yoshimi T, Hamasaki H: Switching to Three Pre-meal Injections of Insulin Glulisine
from the Basal-Bolus Insulin Therapy Improves Glycemic Control in a Patient with Type 2
Diabetes Who Had Anti-Insulin Antibody. Int J Diabetes Dev Ctries 31:240, 2011
59) Moriyama S*, Yanai H* (*equally contribution and corresponding author): Which is the Best
Treatment for Diabetes Complicated with Severe Obesity, Intensive Insulin Therapy or Basal
Supported Oral Therapy or Glucagon-Like Peptide-1 Analog ? J Endocrinol Metab 1:201-203,
2011
60) Yanai H, Adachi H, Hamasaki H: Diabetic Ketosis Caused by the Insulin Analog Aspart-Induced Anti-Insulin Antibody: Successful Treatment With the Newest Insulin Analog Glulisine. Diabetes Care 34:e108, 2011
61) Yanai H, Hamasaki H, Adachi H, Moriyama S, Hirowatari Y: Effects of Liraglutide, a Human
Glucagon-Like Peptide-1 Analog, on Glucose/Lipid Metabolism, and Adipocytokines in
Patients with Type 2 Diabetes. J Endocrinol Metab 1:149-151, 2011.
62) Masui Y, Sako A, Tsuda N, Nishimura S, Seyama Y, Nishida M, Shindo J, Sakamoto T, Kaneko
H, Yanai H (corresponding author): A Difficult Differential Diagnosis of Acute
Cholecystitis in a Patient with Steroid-induced Diabetes. J Clin Med Res 3:331-333, 2011
63) Hamasaki H, Yanai H (corresponding author), Hiraishi C, Moriyama S: A Significant
discrepancy between endocrinological and clinical phenotype and immunological phenotype
in autoimmune polyglandular syndrome Type 3. J Med Cases 3:1-3, 2012
64) Hamasaki H and Yanai H (corresponding author): A Case of Insulin Dependent Diabetes
Associated with Enteroviral Infections. Diabetes Care 35:e25, 2012
65) Adachi H, Yanai H (corresponding author), Hirowatari H: The Underlying Mechanisms for
Olanzapine-induced Hypertriglyceridemia. J Clin Med Res 4:206-208, 2012
66) Yanai H, Moriyama S, Hamasaki H: Effects of switching from liraglutide to exenatide on
body weight and fat, glucose/lipid metabolism, and adipocytokines. Case Study and Case
Report 2:108-112, 2012
67) Hamasaki H, Mishima S, Yanai H (corresponding author): Hyperinsulinemia and insulin
resistance in a patient with type 2 diabetes complicated with myelofibrosis World J
Diabetes 3:156-157, 2012
68) Yoshikawa R, Sako A, Kitagawa H, Hamasaki H, Okubo T, Hiraishi C, Suzuki K, Mishima S,
Yanai H (corresponding author): The Development of Central Pontine Myelinolysis in a Type
1 Diabetic Patient With Anti-Insulin Antibody and Similar Clinical Manifestations to
Autoimmune Polyglandular Syndrome. J Endocrinol Metab 2:181-186, 2012
69) Masui Y, Hamasaki H, Sako A, Moriyama S, Yoshikawa R, Adachi H, Mishima S, Yanai H
(corresponding author): The Development of Repeated Severe Hypothermia in a House in a
Type 2 Diabetic Patient Complicated With Klinefelter’s Syndrome. J Endocrinol Metab
2:195-197, 2012
70) Hamasaki H, Yoshimi T, Yanai H (corresponding author): A patient with Graves' disease
showing only psychiatric symptoms and negativity for both TSH receptor autoantibody and
thyroid stimulating antibody. Thyroid Research 5:19, 2012
71) Yanai H, Hamasaki H, Kaneko H: Complicated diagnosis and defining treatment guidelines
for polyarteritis nodosa Diag Ther Stud 1:34-36, 2012
72) Hamasaki H, Yanai H* (*equally contribution and corresponding author): Diagnosis of
Hypoglycemia due to Over-Dosage of Insulin Analog, Insulin Lispro. J Endocrinol Metab
2:102-103, 2012
73) Yanai H, Hirowatari Y: A significant association of plasma serotonin to cardiovascular
risk factors and changes in pulse wave velocity in patients with type 2 diabetes. Int J
Cardiol 157:312-313, 2012
74) Yoshida H, Hirowatari Y, Kurosawa H, Manita D, Yanai H, Ito K, Tada N: Estimation of
lipoprotein profile in patients with type II diabetes and its relevance to remnant
lipoprotein cholesterol levels. Atherosclerosis 222:541-544, 2012
75) Tsuda N, Sako A, Okamoto S, Adachi H, Hayakawa T, Makino K, Tsukada K, Yanai H
(corresponding author): A significant association between physical restraint and the
development of venous thromboembolism in psychiatric patients. Int J Cardiol 157:442-443,
2012
76) Yanai H, Adachi H, Hamasaki H, Masui Y, Yoshikawa R, Moriyama S, Mishima S, Sako A:
Effects of 6-Month Sitagliptin Treatment on Glucose and Lipid Metabolism, Blood Pressure,
Body Weight and Renal Function in Type 2 Diabetic Patients: A Chart-Based Analysis. J
Clin Med Res 4:251-258, 2012
77) Yoshida H, Shoda T, Yanai H, Ikewaki K, Kurata H, Ito K, Furutani N, Tada N, Witztum JL,
Tsimikas S: Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers
in patients with dyslipidemia. Atherosclerosis 226:161-164, 2013
78) Yanai H, Hirowatari Y. Serum adiponectin levels are significantly associated with
favorable metabolic parameters and elevation of atherosclerotic markers. Int J Cardiol
167:3065-3066, 2013
79) Hamasaki H, Moriyama S, Yanai H (corresponding author): A crosstalk between
macroangiopathy and microangiopathy in type 2 diabetes. Int J Cardiol 168:550-551, 2013
80) Takase S, Osuga JI, Fujita H, Hara K, Sekiya M, Igarashi M, Takanashi M, Takeuchi Y,
Izumida Y, Ohta K, Kumagai M, Nishi M, Kubota M, Masuda Y, Taira Y, Okazaki S, Iizuka Y,
Yahagi N, Ohashi K, Yoshida H, Yanai H, Tada N, Gotoda T, Ishibashi S, Kadowaki T, Okazaki
H: Apolipoprotein C-II Deficiency with No Rare Variant in the APOC2 Gene. J Atheroscler
Thromb 20:481-493, 2013
81) Hamasaki H, Yanai H (corresponding author), Mishima S, Mineyama T, Yamamoto-Honda R,
Kakei M, Ezaki O and Noda M: Correlations of non-exercise activity thermogenesis to
metabolic parameters in Japanese patients with type 2 diabetes. Diabetology & Metabolic
Syndrome 5:26, 2013
82) Yanai H, Moriyama S, Hirowatari Y, Kaneko H: Very low density lipoprotein, chylomicron
and lipoprotein (a) are more useful to detect the development of macrophage activation
syndrome in adult-onset still's disease as compared with cytokines and triglyceride. Am
J Hematol 88:828-830, 2013
83) Yanai H, Adachi H, Hamasaki H: What Induces Diabetic Ketoacidosis or Lactic Acidosis in
Diabetic Alcoholic Patients Complicated with Chronic Calcific Pancreatitis? American
Journal of Medicine and Medical Sciences 3:57-60, 2013
84) Yanai H: Effects of Sitagliptin May Depend on Clinical and Laboratory Data at the Baseline.
J Endocrinol Metab 3:78-80, 2013
85) Ito K, Yoshida H, Yanai H, Kurosawa H, Sato R, Manita D, Hirowatari Y, Tada N: Relevance
of intermediate-density lipoprotein cholesterol to Framingham risk score of coronary heart
disease in middle-aged men with increased non-HDL cholesterol. Int J Cardiol 168:3853-
3858, 2013
86) Hamasaki H, Yanai H (corresponding author), Kakei M, Ezaki O, Noda M: Non-exercise
activity thermogenesis is associated with markers for diabetic microangiopathy in Japanese
female patients with type 2 diabetes. Int J Cardiol 168:4836-4837, 2013
87) Hamasaki H, Yanai H (corresponding author): Arterial Stiffness Is Inversely Related to
Plasma Adiponectin Levels in Young Normotensive Patients With Type 1 Diabetes. Diabetes
Care 36:e186, 2013
88) Hamasaki H, Nakayama T, Yamaguchi A, Moriyama S, Katsuyama H, Kakei M, Yanai H
(corresponding author): Comparison of Glycemic Variability by Using Insulin Glargine and
Insulin Degludec in Japanese Patients With Type 1 Diabetes, Monitored by Continuous
Glucose Monitoring: A Preliminary Report. J Endocrinol Metab 3:138-146, 2013
89) Katsuyama H, Hiraishi C, Hakoshima Y, Hamasaki H, Yanai H (corresponding author): Severe
thrombocytopenia due to repaglinide in a patient with type 2 diabetes. Diabetes Care
36:e36, 2013
90) Hamasaki H, Hiraishi C, Yanai H (corresponding author): Severe angioedema induced by
angiotensin II receptor blocker. Int J Cardiol 168:e15-16, 2013
91) Yanai H, Adachi H, Sako A, Hirowatari Y: Effects of an Inhibitor of 3β-Hydroxysteroid
Dehydrogenase on Glucose, Lipid Metabolism and Adipose Tissue in a Patient With Type 2
Diabetes. J Endocrinol Metab 3:119-123, 2013
92) Hamasaki H, Yanai H (corresponding author): The development of angioedema in a patient
with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin. Int J
Cardiol 168:e106, 2013
93) Hamasaki H, Mukaino T, Kaneko H, Mitsui T, Moriyama S, Hasegawa T, Yanai H (corresponding
author): Pseudopseudo-hypoparathyroidism With a Novel Mutation in the GNAS Gene Showing
Thin Bones of Extremities and Ossification of Entheses. J Endocrinol Metab 3:150-152,
2013
94) Hamasaki H, Narita Z, Ichinose T, Tanaka Y, Yanai H (corresponding author): Pulmonary
congestion due to hypothyroidism and nephrotic syndrome induced by cold agglutinins. Ann
Hematol 93:717-718, 2014
95) Hamasaki H, Yanai H* (*corresponding author): An absence of atherosclerosis progression
in a type 2 diabetic patient with multiple atherosclerotic risk factors, complicated
with liver cirrhosis. Int J Cardiol 172:e253-254, 2014
96) Adachi H, Sako A, Ikuta A, Nakamura K, Machitori A, Mishima S, Yanai H: The Case of
Pyelonephritis and Renal Cyst Infection Diagnosed by Diffusion-Weighted Magnetic Resonance
Imaging. World J Nephrol Urol 3:106-109, 2014
97) Yanai H: Dipeptidyl peptidase-4 inhibitor Sitagliptin significantly reduced hepatitis C
virus replication in a diabetic patient with chronic hepatitis C virus infection.
Hepatobiliary Pancreat Dis Int 13:556, 2014
98) Ichinose T, Moriyama S, Sako A, Yanai H, Kaneko H, Tanaka Y: Usefulness of Decreasing
Number of Negative T Wave Leads on Electrocardiography for Predicting the Improvement of
Pulmonary Hypertension;A Case Report. Juntendo Medical Journal 60:454-457, 2014
99) Moriyama S and Yanai H (corresponding author): The addition of metformin and glucagon-
like peptide-1 receptor agonist or dipeptidyl-peptidase-4 inhibitor to insulin for latent
autoimmune diabetes in adults. Int J Diabetes Dev Ctries 34:56, 2014
100) Sako A, Yasunaga H, Horiguchi H, Fushimi K, Yanai H, Uemura N; Prevalence and in-hospital
mortality of gastrostomy and jejunostomy in Japan: a retrospective study with a national
administrative database. Gastrointest Endosc 80:88-96, 2014
101) Yamamoto-Honda R, Takahashi Y, Yamashita S, Mori Y, Yanai H, Mishima S, Kajio H, Handa N,
Shimokawa K, Yoshida A, Kitazato H, Shimbo T, Kawazu S, Noda M: Constructing the National
Center Diabetes Database. Diabetology Int 5:234-243, 2014
102) Hamasaki H, Yanai H (corresponding author), Kakei M, Noda M and Ezaki O: The validity of
the non-exercise activity thermogenesis questionnaire evaluated by objectively measured
daily physical activity by the triaxial accelerometer. BMC Sports Science, Medicine and
Rehabilitation 6:27, 2014
103) Katsuyama H, Adachi H, Hamasaki H, Moriyama S, Sako A, Yanai H (corresponding author):
Significant Differences in Effects of Sitagliptin Treatment on Body Weight and Lipid
Metabolism Between Obese and Non-obese Patients With Type 2 Diabetes. J Endocrinol Metab.
4:136-142, 2014
104) Hamasaki H, Yanai H (corresponding author): Switching from insulin glargine to insulin
degludec reduced HbA1c, daily insulin doses and anti-insulin antibody in anti-insulin
antibody-positive subjects with type 1 diabetes. Diabetes Metab 40:481-482, 2014
105) Katsuyama H, Kawaguchi A, Yanai H (corresponding author): Not visceral fat area but the
ratio of visceral to subcutaneous fat area is significantly correlated with the marker
for atherosclerosis in obese subjects. Int J Cardiol 179:112-113, 2015
106) Hamasaki H, Yanai H (corresponding author), Kakei M, Noda M, Ezaki O: The association
between daily physical activity and plasma B-type natriuretic peptide in patients with
glucose intolerance: a cross-sectional study. BMJ Open 5:e006276, 2015
107) Yanai H, Hirowatari Y: Association of Serum Uric Acid Concentration With Metabolic Risk
Factors in Patients With Type 2 Diabetes. J Clin Hypertens (Greenwich). 17:741, 2015
108) Katsuyama H, Sako A, Adachi H, Hamasaki H, Yanai H (corresponding author): Effects of 6-
month sitagliptin treatment on metabolic parameters in diabetic patients taking oral
glucocorticoids: a retrospective cohort study. J Clin Med Res. 7:479-84, 2015
109) Yanai H, Hirowatari Y: Different associations of body mass index and visceral fat area
with metabolic parameters and adipokines in Japanese patients with type 2 diabetes.
Diabetes Metab. 41:261-2, 2015
110) Hamasaki H, Yanai H, Kakei M, Noda M, Ezaki O: Higher daily energy expenditure by
locomotive activities is favorably associated with cardiac autonomic nervous function and
arterial stiffness. Int J Cardiol. 194:70-1, 2015
111) Hamasaki H, Noda M, Moriyama S, Yoshikawa R, Katsuyama H, Sako A, Mishima S, Kakei M,
Ezaki O, Yanai H: Daily Physical Activity Assessed by a Triaxial Accelerometer Is
Beneficially Associated with Waist Circumference, Serum Triglycerides, and Insulin
Resistance in Japanese Patients with Prediabetes or Untreated Early Type 2 Diabetes. J
Diabetes Res. 2015:526201, 2015
112) Sako A, Yasunaga H, Matsui H, Fushimi K, Hamasaki H, Katsuyama H, Tsujimoto T, Goto A,
Yanai H: Hospitalization for Hypoglycemia in Japanese Diabetic Patients: A Retrospective
Study Using a National Inpatient Database, 2008-2012. Medicine (Baltimore). 94:e1029,
2015
113) Hamasaki H, Kawashima Y, Adachi H, Moriyama S, Katsuyama H, Sako A, Yanai H:
Associations between lower extremity muscle mass and metabolic parameters related to
obesity in Japanese obese patients with type 2 diabetes. PeerJ. 3:e942, 2015
114) Hamasaki H, Kawashima Y, Tamada Y, Furuta M, Katsuyama H, Sako A, Yanai H: Associations
of Low-Intensity Resistance Training with Body Composition and Lipid Profile in Obese
Patients with Type 2 Diabetes. PLoS One. 10:e0132959, 2015
115) Adachi H, Yanai H (corresponding author): Adverse drug reaction: A possible case of
glimepiride-induced syndrome of inappropriate antidiuretic hormone secretion. Diabetes
Metab. 41(2):176-7, 2015
116) Yoshikawa R, Hishinuma R, Kaneko H, Yanai H (corresponding author): Agranulocytosis due
to an α-glucosidase inhibitor, voglibose. Int J Diabetes Dev Ctries 36:384-5, 2015.
117) Hamasaki H, Hakoshima M, Yanai H: Periaortitis induced by metformin. Diabetes Metab.
41:344-5, 2015
118) Hamasaki H, Moriyama S, Yanai H: A possible difference in the mechanism for postprandial
hypoglycemia associated with dumping syndrome between patients with and without type 2
diabetes. Obes Res Clin Pract. 9:622-4, 2015
119) Hamasaki H, Kakei M, Yanai H: Thyroid gland in patients with psychiatric disorders is
significantly smaller than that in individuals without psychiatric disorders. Prim Care
Companion CNS Disord 17:10, 2015
120) Hamasaki H, Takeuchi Y, Masui Y, Ohta Y, Abe K, Yoshino H, Yanai H: Development of diabetes in a familial amyotrophic lateral sclerosis patient carrying the I113T SOD1 mutation. Case Report. Neuro Endocrinol Lett. 36:414-6, 2015
121) Kawaguchi A, Katsuyama H, Yanai H (corresponding author): Effects of Lifestyle
Modification Program, KOHNODAI Program, on Metabolic Parameters in Japanese Obese People.
J J Diab Endocrin 1;011-015, 2015
122) Hamasaki H, Ezaki O, Yanai H: Nonexercise Activity Thermogenesis is Significantly Lower
in Type 2 Diabetic Patients With Mental Disorders Than in Those Without Mental Disorders:
A Cross-sectional Study. Medicine (Baltimore) 95:e2517, 2016
123) Hamasaki H, Yanai H: Plasma B-Type Natriuretic Peptide Levels May Increase Because
of Fat Mass Loss by Metformin or Sodium-Glucose Transporter 2 Inhibitors Treatment. J
Endocrinol Metab 6:12-17, 2016
124) Yanai H: High-titer of autoantibody at onset do not predict pancreatic beta-cell fate.
Diabetes Metab 42:475-476, 2016
125) Katsuyama H, Fukunaga T, Hamasaki H, Adachi H, Moriyama S, Kawaguchi A, Mishima S, Sako
A, Yanai H (corresponding author): The Influences of Withdrawal and Daily Dose Reduction
of Pioglitazone on Metabolic Parameters in Patients with Type 2 Diabetes: A Retrospective
Longitudinal Observational Study. J Clin Med Res 8:585-90, 2016
126) Katsuyama H, Matsuura S, Yanai H (corresponding author): Effects of the Switching from
High-Purity Eicosapentaenoic Acid to Combination of Eicosapentaenoic Acid and
Docosahexaenoic Acid on Metabolic Parameters: A Retrospective Longitudinal Study. J
Endocrinol Metab 6:75-9, 2016
127) Moriyama S, Yoshikawa R, Katsuyama H, Hamasaki H, Adachi H, Yanai H (corresponding author):
Clinical, Endocrinological?and Immunological Characteristics of Japanese Patients with
Autoimmune Polyglandular Syndrome Type 3a. J Endocrinol Metab 6:46-51, 2016
128) Katsuyama H, Yanai H (corresponding author): An Influence of the Estimated Glomerular
Filtration Rate on Improvement in Metabolic Parameters by Sodium-Glucose Cotransporter 2
Inhibitors. J Clin Med Res 8:486-8, 2016
129) Yanai H, Hirowatari Y, Ito K, Kurosawa H, Tada N, Yoshida H: Understanding of Diabetic
Dyslipidemia by Using the Anion-Exchange High Performance Liquid Chromatography Data.
J Clin Med Res 8:424-6, 2016
130) Katsuyama H, Hamasaki H, Adachi H, Moriyama S, Kawaguchi A, Sako A, Mishima S, Yanai H
(corresponding author): Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic
Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis. J Clin Med Res 8:237-
43, 2016
131) Yanai H: Correlations of Arterial Stiffness and Augmentation Index With Metabolic
Risk Factors in Patients With Type 2 Diabetes. J Clin Hypertens (Greenwich) 18:593-4,
2016
132) Yamamoto-Honda R, Takahashi Y, Yoshida Y, Kawazu S, Iwamoto Y, Kajio H, Yanai H, Mishima
S, Shimbo T, Noda M: Body mass index and the risk of cancer incidence in patients with
type 2 diabetes in Japan: Results from the National Center Diabetes Database. J Diabetes
Investig 7:908-914, 2016
133) Yoshikawa R, Moriyma S, Masui Y, Yanai H (corresponding author): Incidence, Age and Gender
of Subjects With the Calcium Pyrophosphate Deposition Around the Dens, and Clinical
Characteristics of Patients With Crowned Dens Syndrome. J Endocrinol Metab 6:143-148,
2016
134) Hamasaki H, Kawashima Y, Yanai H: Serum Zn/Cu Ratio Is Associated with Renal Function, Glycemic Control, and Metabolic Parameters in Japanese Patients with and without Type 2 Diabetes: A Cross-sectional Study. Front Endocrinol (Lausanne). 7:147, 2016
135) Ueyama M, Nishida N, Korenaga M, Korenaga K, Kumagai E, Yanai H, Adachi H, Katsuyama H,
Moriyama S, Hamasaki H, Sako A, Sugiyama M, Aoki Y, Imamura M, Murata K, Masaki N,
Kawaguchi T, Torimura T, Hyogo H, Aikata H, Ito K, Sumida Y, Kanazawa A, Watada H,
Okamoto K, Honda K, Kon K, Kanto T, Mizokami M, Watanabe S: The impact of PNPLA3 and
JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes
mellitus. J Gastroenterol. 51:370-9, 2016
136) Yanai H, Hirowatari Y: Fasting serum C-peptide levels (>1.6ng/mL) can predict the
presence of insulin resistance in Japanese patients with type 2 diabetes. Diabetes Metab.
2017;43(1):97-98.
137) Hamasaki H, Kawashima Y, Yanai H: The association between hand grip strength and non-exercise activity thermogenesis in patients with type 2 diabetes. Diabetes Metab. 2017;43(3):284-286.
138) Adachi H, Katsuyama H, Yanai H (corresponding author): The low dose (7.5mg/day) pioglitazone is beneficial to the improvement in metabolic parameters without weight gain and an increase of risk for heart failure. Int J Cardiol. 227:247-248, 2017
139) Sakurai A, Yanai H, Ishida T, Kuwata H, Kamei K, Izumi S: Possible relationship between
organizing pneumonia and chronic pulmonary aspergillosis: A case report and literature
review. Respir Investig. 55:74-78, 2017
140) Yanai H, Katsuyayama H: A Possible Mechanism for Renoprotective Effect of Sodium-Glucose
Cotransporter 2 Inhibitor: Elevation of Erythropoietin Production. J Clin Med Res. 9:178-179, 2017
141) Nanasawa H, Sako A, Mitsutsuka T, Nonogaki K, Kondo T, Mishima S, Uju Y, Ito T, Enomoto
T, Hayakawa T, Yanai H. Development of diabetes mellitus associated with quetiapine: A
case series. Medicine (Baltimore). 96:e5900, 2017
142) Yamamoto-Honda R, Takahashi Y, Mori Y, Yamashita S, Yoshida Y, Kawazu S, Iwamoto Y, Kajio
H, Yanai H, Mishima S, Handa N, Shimokawa K, Yoshida A, Watanabe H, Ohe K, Shimbo T, Noda
M. A positive family history of hypertension might be associated with an accelerated onset
of type 2 diabetes: Results from the National Center Diabetes Database (NCDD-02). Endocr
J. 2017;64(5):515-520.
143) Yanai H, Hakoshima M, Adachi H. What Properties of Sodium-Glucose Cotransporter 2
Inhibitors Determine the Improvement in Hemoglobin A1c and Body Weight? J Clin Med Res.
2017;9(5):446-448.
144) Yanai H, Takano Y, Adachi H, Kawaguchi A, Hakoshima M, Waragai Y, Harigae T, Hamasaki H, Katsuyama H, Kaga T, Sako A. Data Collection and the Questionnaires for the Effective Use of Biobank for Metabolic Disorders. J Endocrinol Metab. 2017;7(1):1-4.
145) Akiyama T, Hamasaki H, Adachi H, Yanai H. Understanding of Dose-Response of Metformin by Using Continuous Glucose Monitoring. J Endocrinol Metab. 2017;7(2):72-74.
146) Yanai H, Hakoshima M, Adachi H, Kawaguchi A, Waragai Y, Harigae T, Masui Y, Kakuta K,
Hamasaki H, Katsuyama H, Kaga T, Sako A. Effects of Six Kinds of Sodium-Glucose
Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its
Correlations With Baseline Data. J Clin Med Res. 2017;9(5):446-448.
147) Hamasaki H, Katsuyama H, Sako A, Yanai H. Short sleep duration is associated with B-type natriuretic peptide levels and predicts the death of Japanese patients with type 2 diabetes. Sleep Med. 2017;36:1-5.
148) Kakuta K, Adachi H, Yanai H. Construction of Effective and Safe Glycemic Control in the Elderly by Using Continuous Glucose Monitoring. J Endocrinol Metab. 2017;7(3):75-76
149) Sako A, Yasunaga H, Matsui H, Fushimi K, Hamasaki H, Katsuyama H, Tsujimoto T, Goto A, Yanai H. Hospitalization with hypoglycemia in patients without diabetes mellitus: A retrospective study using a national inpatient database in Japan, 2008-2012. Medicine (Baltimore). 2017;96(25):e7271.
150) Hamasaki H, Kawashima Y, Katsuyama H, Sako A, Goto A, Yanai H. Association of handgrip strength with hospitalization, cardiovascular events, and mortality in Japanese patients with type 2 diabetes. Sci Rep. 2017;7(1):7041.
151) Yanai H, Hakoshima M. Eicosapentaenoic Acid for Diabetic Abducens Nerve Palsy. J Endocrinol Metab. 2017;7(4):131-132.
152) Sugimoto T, Hakoshima M, Hamasaki H, Yanai H. Abdominal Abscess due to Perforation of the Terminal Ieum Caused by a Fish Bone Treated by the Conservative Treatment Using Antibiotics. J Med Cases. 2017; 8(11):361-364.
153) Koguchi A, Adachi H, Yanai H. The Application of Sodium-Glucose Cotransporter 2
Inhibitors to Chronic Kidney Disease Stage 4. J Clin Med Res. 2017;9(12):1029-1031.
154) Yanai H. A decrease in glutamic acid decarboxylase autoantibody levels with sitagliptin use in patients with latent autoimmune diabetes in adults. Diabetes Metab. 2018;44(2):188-189.
155) Yanai H, Adachi H, Hakoshima M. Understanding of hypertension and heart failure in patients with type 2 diabetes by studying effects of sodium-glucose cotransporter 2 inhibitors on plasma B-type natriuretic peptide levels. J Clin Hypertens (Greenwich). 2018;20(2):411-412.
156) Yamamoto-Honda R, Takahashi Y, Mori Y, Yamashita S, Yoshida Y, Kawazu S, Iwamoto Y, Kajio H, Yanai H, Mishima S, Handa N, Shimokawa K, Yoshida A, Watanabe H, Ohe K, Shimbo T, Noda M. Changes in Antidiabetic Drug Prescription and Glycemic Control Trends in Elderly Patients with Type 2 Diabetes Mellitus from 2005-2013: An Analysis of the National Center Diabetes Database (NCDD-03). Intern Med. 2017
157) Hamasaki H, Yanai H. Association of Serum Zn/Cu Ratio With Handgrip Strength and
Hospitalization in Japanese Patients With Type 2 Diabetes. J Endocrinol Metab. 2017;
7(6):199-200.
158) Harigae H, Tsuda N, Hashimoto H, Yanai H. Usefulness of Scintigraphy to Evaluate Adrenal
Tumors. J Endocrinol Metab. 2018;8(1):13-14.
159) Hakoshima M, Yanai H, Kakuta K, Adachi H. Sodium-Glucose Cotransporter 2 Inhibitors
Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive
Insulin Therapy. J Clin Med Res, Vol.10, 493-498, 2018 (IF:0) (Corresponding author)
160) Yanai H. Liver Dysfunction due to Anti-Thyroid Drugs. J Endocrinol Metab, Vol.8, 52-
53, 2018 (IF:0)
161) Moriyama S, Yanai H, Takeuchi Y, Hayakawa T. Effects of an orexin receptor antagonist on
blood pressure and metabolic parameters. J Clin Hypertens (Greenwich). 2018 May;20(5):978-
980.
162) Yanai H, Hakoshima M, Adachi H. Which Factor Determines the Duration Required for Relief
of Glucotoxicity by the Intensive Insulin Therapy? J Clin Med Res. 2018;10(7):606-608.
163) Yanai H. Bofutsushosan Significantly Ameliorated Betamethasone-Induced Cushing's Syndrome.
J Clin Med Res. 2018;10(8):668-669.
164) Katsuyama H, Hamasaki H, Yanai H. Habit of Bathing or Showering is Beneficially Associated
with Body Weight and Abdominal Circumference in Patients with Type 2 Diabetes. J Clin Med
Res. 2018;10(9):728-731.
165) Yanai H, Moriyama S. A Different Effect of an Orexin Receptor Antagonist on Metabolic
Parameters Between Diabetic Patients and Non-Diabetic Patients. J Clin Med Res.
2018;10(10):795
166) Yanai H, Adachi H, Hakoshima M, Katsuyama H. An Effective Insulin Therapy In Combination With Sodium-Glucose Cotransporter 2 Inhibitors. J Clin Med Res. 2019;11(1):76-79.
167) Hamasaki H, Furuta M, Yanai H. Validity of visceral fat area measurement by bioelectrical impedance analysis in Japanese obese individuals. Curr Diabetes Rev. 2019 Jan 27. doi: 10.2174/1573399815666190128113657.
168) Katsuyama H, Yanai H. Does Metformin Assist New Anti-Diabetic Drugs to Succeed? J Clin Med Res. 2019;11(2):151-155.
169) Yoshikawa R, Yanai H, Moriyama S, Furugaki N. Associations of Pericardial Fat Area Determined by Routine Chest Computed Tomography with Coronary Risk Factors and Coronary Artery Disease. J Clin Med Res. 2019;11(4):289-296.
170) Hakoshima M, Yanai H, Komatsuzaki S, Kawaguchi A, Hamasaki H, Katsuyama H. Streptococcal Infection Can Be the Trigger for Thyroid Storm. J Clin Med Res. 2019;11(5):383-384.
171) Katsuyama H, Yanai H. Effects of Metformin Monotherapy on Metabolic Parameters in Japanese Patients with Type 2 Diabetes. J Endocrinol Metab. 2019;9(1-2):18-21.
172) Yanai H, Hakoshima M, Katsuyama H. Clinical, Biochemical, Hematological, Endocrinological and Immunological Differences Between Graves’Disease Patients With and Without Thyroid Storm. J Clin Med Res. 2019;11(6):452-457.
173) Yanai H, Hakoshima H, Katsuyama H. Differences in Clinical and Laboratory Findings Among Graves’ Disease, Painless Thyroiditis and Subacute Thyroiditis Patients With Hyperthyroidism J Endocrinol Metab. 2019;9(3):37-42
174) Yanai H, Moriyama S. Lipid Abnormalities During Acute Metabolic Complications of Diabetes in Japanese Diabetic Patients J Endocrinol Metab. 2019;9(3):79-80.
175) Katsuyama H, Yanai H, Hakoshima M. Renoprotective Effect of Xanthine Oxidase Inhibitor, Topiroxostat. J Clin Med Res. 2019;11(8):614-616.
176) Masui Y, Yanai H, Hiraga K,Tsuda N, Kano T. Effects of Anti-Malarial Drug,
Hydroxychloroquine, on Glucose and Lipid Metabolism in Japanese Population. J Endocrinol
Metab.2019;9(5):159-164.
177) Yoshida H, Tada H, Ito K, Kishimoto Y, Yanai H, Okamura T, Ikewaki K, Inagaki K, Shoji T,
Bujo H, Miida T, Yoshida M, Kuzuya M, Yamashita S. Reference Intervals of Serum Non-
Cholesterol Sterols by Gender in Healthy Japanese Individuals. J Atheroscler Thromb. 2019
Sep 5. doi: 10.5551/jat.50187. [Epub ahead of print]
178) Ruilope LM,et al. Design and Baseline Characteristics of the Finerenone in Reducing
Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol.
2019;50(5):345-356.
179) Bakris GL,et al. Design and Baseline Characteristics of the Finerenone in Reducing Kidney
Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;
50(5):333-344.
180) Waragai Y, Yanai H, Kondo T, Takeuchi Y, Hayakawa T, Sako A. The Risk Factors for
Asymptomatic Pyuria Among Patients With Type 2 Diabetes. J Endocrinol Metab. 2019;9(6):
193-198.
181) Katsuyama H, Hakoshima M, Iijima T, Adachi H, Yanai H. Effects of Sodium-Glucose
Cotransporter 2 Inhibitors on Hepatic Fibrosis in Patients With Type 2 Diabetes:
A Chart-Based Analysis. J Endocrinol Metab. 2020;10(1):1-7. 182) Yanai H, Katsuyama H. Statin Intolerance in Familial Hypercholesterolemia. J Endocrinol
Metab. 2020;10(1):30-31.
183) Yanai H. A Significance of High Prevalence of Diabetes and Hypertension in Severe COVID-
19 Patients. J Clin Med Res. 2020;12(6):389-392.
184) Yanai H. Adiposity is the Crucial Enhancer of COVID-19. Cardiol Res. 2020 Oct;11(5):353-
354.
185) Yanai H. Significant Correlations of SARS-CoV-2 Infection With Prevalence of Overweight
/Obesity and Mean Body Mass Index in the SARS-CoV-2 Endemic Countries. Cardiol Res. 2020;
11(6):412-414.
186) Sugiyama M, Kinoshita N, Ide S, Nomoto H, Nakamoto T, Saito S, Ishikane M, Kutsuna S,
Hayakawa K, Hashimoto M, Suzuki M, Izumi S, Hojo M, Tsuchiya K, Gatanaga H, Takasaki J,
Usami M, Kano T, Yanai H, Nishida N, Kanto T, Sugiyama H, Ohmagari N, Mizokami M. Serum
CCL17 level becomes a predictive marker to distinguish between mild/moderate and
severe/critical disease in patients with COVID-19. Gene. 2021;766:145145.
187) Uju Y, Kanzaki T, Yamasaki Y, Kondo T, Nanasawa H, Takeuchi Y, Yanagisawa Y, Kusanishi S,
Nakano C, Enomoto T, Sako A, Yanai H, Mishima S, Mimori S, Igarashi K, Takizawa T, Hayakawa
T. A cross-sectional study on metabolic similarities and differences between inpatients
with schizophrenia and those with mood disorders. Ann Gen Psychiatry. 2020 Sep 22;19:53.
doi: 10.1186/s12991-020-00303-5. eCollection 2020.
Review
1) Yanai H, Morimoto M?. Diagnosis of nonalcoholic fatty liver disease. JAMA 290:1577,
2003
2) Yoshida H, Yanai H, Namiki Y, Fukatsu-Sasaki K, Furutani N, Tada N: Neuroprotective effects
of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drugs Review
12:9-20, 2006
3) Yanai H, Yoshida H, Tomono Y, Tada N, Chiba H: A possible contribution of a general
glycosphingolipid transporter, GM2 activator protein, to atherosclerosis. J Atheroscler
Thromb 13:281-285, 2006
4) Yanai H, Yoshida H, Tada N. Body-mass index and gastroesophageal reflux in women. N
Engl J Med 355:848-9, 2006
5) Yanai H, Yoshida H, Tomono Y, Tada N: Atherosclerosis imaging in statin intervention
trials.
QJM 100:253-262, 2007
6) Yanai H, Tomono Y, Ito K, Furutani N, Yoshida H, Tada N: Diacylglycerol oil for the
metabolic syndrome. Nutr J 6:43, 2007
7) Yanai H, Tomono Y, Ito K, Furutani N, Yoshida H, Tada N: The underlying mechanisms for
development of hypertension in the metabolic syndrome. Nutr J 7:10, 2008
8) Yanai H, Ito K, Yoshida H, Tada N: Antihypertensive effects of astaxanthin. Integrated
Blood Pressure Control 1:1-3, 2008
9) Yanai H, Adachi H: Types of Diabetes that the Dipeptidyl Peptidase-4 Inhibitor May Act
Effectively and Safely. The Open Diabetes Journal 3:29-33, 2010
10) Yanai H, Yoshida H, Hirowatari Y, Tada N: Diacylglycerol for Obesity-Serotonin Hypothesis.
Proceedings of the 8th International Conference Functional Foods and Chronic Diseases:
Science and Practice 71-72, 2011
11) Yanai H, Adachi H, Hamasaki H, Mishima S: The Treatment for Anti-insulin Antibody-mediated
Immunological Insulin Resistance. J Endocrinol Metab 1:234-236, 2011
12) Yanai H, Hamasaki H, Tsuda N, Adachi H, Yoshikawa R, Moriyama S, Masui Y, Mishima S: Group
B streptococcus infection and diabetes: A review. Journal of Microbiology and
Antimicrobials 4:1-5, 2012
13) Yanai H, Yoshida H, Hirowatari Y, Tada N: Therapeutic Application of Diacylglycerol for
Obesity: Serotonin Hypothesis. Functional Foods in Health and Disease 2:1-10, 2012
14) Hamasaki H, Yanai H. Comment on: Tsiakou et al. Arterial Stiffness Is Inversely Related
to Plasma Adiponectin Levels in Young Normotensive Patients With Type 1 Diabetes.
Diabetes Care, 36:e186, 2013 (IF, 8.934) (Corresponding author)
15) Yanai H, Katsuyama H, Hamasaki H, Abe S, Tada N, Sako A: Effects of Alcohol Consumption
on HDL Metabolism in Asian Populations. J Endocrinol Metab. 4:47-50, 2014
16) Yanai H, Katsuyama H, Hamasaki H, Abe S, Tada N, Sako A: Effects of Soy Protein and
Isoflavones Intake on HDL Metabolism in Asian Populations. J Endocrinol Metab. 4:51-55,
2014
17) Yanai H, Katsuyama H, Hamasaki H, Adachi H, Moriyama S, Sako A: Expert Opinion-The
Application of Dipeptidyl Peptidase 4 Inhibitor to the Treatment for Hepatitis C Virus
Infection. Int J Diabetes Clin Diagn 1:101, 2014
18) Yanai H, Katsuyama H, Hamasaki H, Abe S, Tada N, Sako A: Effects of Carbohydrate and
Dietary Fiber Intake, Glycemic Index and Glycemic Load on HDL Metabolism in Asian
Populations. J Clin Med Res 6:321-326, 2014
19) Yanai H, Katsuyama H, Kawaguchi A, Moriyama S, Hamasaki H, Ohkubo H, Osako K, Sanada A:
Lifestyle Modification Program, KOHNODAI Program. J J Diab Endocrin 1:005, 2014
20) Yanai H, Hamasaki?H, Katsuyama H, Adachi H, Moriyama S, Sako A: Effects of Intake of Fish
or Fish Oils on the Development of Diabetes. J Clin Med Res 7:8-12, 2015
21) Yanai H, Katsuyama H, Hamasaki H, Abe S, Tada N, Sako A: Effects of Dietary Fat Intake on
HDL Metabolism in Asian Populations. J Clin Med Res 7:145-149, 2015
22) Yanai H, Adachi H, Katsuyama H, Hamasaki H, Sako A: Anti-atherosclerotic effects of konjac.
Functional Foods in Health and Disease. 5:136-144, 2015.
23) Yanai H, Adachi H, Katsuyama H, Moriyama S, Hamasaki H, Sako A: Causative anti-diabetic
drugs and the underlying clinical factors for hypoglycemia in patients with diabetes.
World J Diabetes 6:30-36, 2015
24) Yanai H: Nutrition for Sarcopenia. J Clin Med Res 7:926-31, 2015
25) Yanai H: Which is Better to Prevent Cardiovascular Events, Only EPA or the Combination
of EPA and DHA? J Endocrinol Metab. 6:101-3, 2016
26) Yanai H, Katsuyama H, Hamasaki H, Adachi H, Moriyama S, Yoshikawa R, Sako A:
Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond
Glucose Lowering. J Clin Med Res 8:10-4, 2016
27) Yanai H: Think About the Application of Vitamin E to Heterozygous Familial
Hypobetalipoproteinemia to Prevent Liver Cirrhosis and Hepatocellular Carcinoma. J
Endocrinol Metab. 6:133-134, 2016
28) Yanai H: The Metabolic Disorder and Metabolic Disorder-Related Diseases Model. J Endocrinol
Metab. 6:165-166, 2016
29) Yanai H: Effects of N-3 Polyunsaturated Fatty Acids on Dementia. J Clin Med Res. 9:1-9,
2017
30) Yanai H, Adachi H, Kawaguchi A, Hakoshima M, Waragai Y, Harigae T, Masui Y, Kakuta H,
Hamasaki H, Katsuyama H, Sako A. The anti-atherosclerotic effects of tomatoes. Functional
Foods in Health and Disease 2017;7(6);411-428
31) Yanai H. VLDL Is the Leading Actor in Lipid Abnormality in Patients With Diabetes and
Obesity. J Endocrinol Metab. 2017;7(4):101-102.
32) Yanai H, Adachi H. The Low-Dose (7.5 mg/day) Pioglitazone Therapy. J Clin Med Res.
2017;9(10):821-825.
33) Yanai H. Major Component Diseases, Autoantibodies, and Typical Clinical and
Endocrinological Findings Observed in Each Type of Polyglandular Autoimmune Syndrome. J
Endocrinol Metab. 2017;7(5):133-134.
34) Yanai H. Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2
Diabetes. Ann Transl Med. 2017;5(23):470.
35) Yanai H. A New Potential of a Sleeping Pill. Remedy Open Access. 2017;2:1055.
36) Yanai H. Sodium-glucose Cotransporter 2 Inhibitors for Heart Failure. J Endocrinol Metab.
2017;7(3):98-99
37) Yanai H. Impaired Crosstalk Between Insulin and Glucagon Secretion in Patients With Type
2 Diabetes. J Endocrinol Metab. 2018;8(1):1
38) Yanai H, Masui Y, Katsuyama H, Adachi H, Kawaguchi A, Hakoshima M, Waragai Y, Harigae T,
Sako A. An Improvement of Cardiovascular Risk Factors by Omega-3 Polyunsaturated Fatty
Acids. J Clin Med Res. 2018;10(4):281-289.
39) Yanai H, Adachi H, Masui Y, Katsuyama H, Kawaguchi A, Hakoshima M, Waragai Y, Harigae T,
Hamasaki H, Sako A. Exercise Therapy for Patients With Type 2 Diabetes: A Narrative Review.
J Clin Med Res. 2018;10(5):365-369.
40) Yanai H, Tada N. Effects of Energy and Carbohydrate Intake on Serum High-Density
Lipoprotein-Cholesterol Levels. J Endocrinol Metab. 2018;8(2-3):27-31 (IF:0)
(Corresponding author)
41) Yanai H. The Efficacious and Safe Treatment for Steroid-Induced Hyperglycemia. J Endocrinol
Metab. 2018;8(2-3):15 (IF:0) (Corresponding author)
42) Yanai H. Autoimmune Polyendocrine Syndromes. N Engl J Med. 2018;378(26):2542-3.
43) Yanai H, Tada N. Effects of Glycemic Index and Intake of Dietary Fiber on Serum HDL-
cholesterol Levels. J Endocrinol Metab. 2018;8(4):57-61 (IF:0) (Corresponding author)
44) Katsuyama H, Adachi H, Masui Y, Hakoshima M, Waragai A, Harigae T, Kondo Y, Iijima T,
Yanai H. Diabetes Evaluation Sheet. J Endocrinol Metab. 2018;8(4):55-56.
45) Yanai H, Tada N. Effects of Intake of Soy and Non-Soy Legume on Serum HDL-Cholesterol
Levels. J Endocrinol Metab. 2018;8(5):83-86.
46) Yanai H, Tada N. Effects of Consumption of Various Fatty Acids on Serum HDL-Cholesterol
Levels. J Endocrinol Metab. 2018;8(5):94-99.
47) Yanai H, Tada N. Which Nutritional Factors Are Good for HDL? J Clin Med Res. 2018;
10(12):936-939
48) Yanai H, Yoshida H. Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and
Atherosclerotic Progression: Mechanisms and Perspectives. Int J Mol Sci. 2019;20(5): E1190.
49) Yanai H. Anti-Atherogenic Properties of Extra Virgin Olive Oil. J Endocrinol Metab.
2019;9(1-2):1-2.
50) Yanai H. Thyroid Hormone and Dementia. J Endocrinol Metab.2019;9(4):81.
51) Yanai H. Dipeptidyl Peptidase-4 Inhibitor Versus Sodium-Glucose Cotransporter-2 Inhibitor
in the Management of Type 2 Diabetes. J Endocrinol Metab. 2019;9(5):117-119.
52) Yanai H. Differential Diagnosis of Thyrotoxicosis. J Endocrinol Metab. 2019;9(5):127-132.
53) Yanai H, Hakoshima M, Katsuyama H. The Possible Mechanisms for Improvement of Liver Function
due to Sodium-Glucose Cotransporter-2 Inhibitors. J Clin Med Res. 2019;11(11):769-772.
54) Yanai H, Hirowatari Y, Yoshida H Diabetic dyslipidemia: evaluation and mechanism. Global
Health & Medicine. 2019;1(1):30-35.
55) Yanai H. Favipiravir: A Possible Pharmaceutical Treatment for COVID-19. J Endocrinol Metab.
2020;10(2):33-34.
56) Yanai H. Can Dipeptidyl Peptidase 4 Inhibitor Be the Therapeutic Candidate for the COVID-
19? J Endocrinol Metab. 2020;10(2):35.
57) Yanai H. The Points of Action of Drugs for Treating COVID-19. J Endocrinol Metab. 2020;10(3-
4):57-59.
58) Yanai H. Hyperlipidemia due to Nephrotic Syndrome: Its Effects and Effects of Interventions
on Atherogenesis, Cardiovascular and Renal Outcomes. J Endocrinol Metab. 2020;10(3-4):63-
73.
59) Yanai H, Katsuyama H. An Appropriate Energy Intake Proportion of Three Major Nutrients for
Treatment of Type 2 Diabetes. J Endocrinol Metab. 2020;10(5):113-117.
60) Yanai H. Metabolic Syndrome and COVID-19. Cardiol Res. 2020;11(6):360-365.